ripretinib sold brand name qinlock medication treatment adults advanced gastrointestinal stromal tumor gist type tumor originates gastrointestinal taken ripretinib inhibits activity kinases kit pdgfra helps keep cancer cells common side effects include alopecia hair loss fatigue nausea abdominal pain constipation myalgia muscle pain diarrhea decreased appetite palmarplantar erythrodysesthesia syndrome skin reaction palms soles ripretinib approved medical use united states may australia july european union november ripretinib first new drug specifically approved united states fourthline treatment advanced gastrointestinal stromal tumor gist ripretinib indicated treatment adults advanced gastrointestinal stromal tumor gist type tumor originates gastrointestinal tract received prior treatment three kinase inhibitor therapies including gist type stomach bowel esophagus common side effects include alopecia hair loss fatigue nausea abdominal pain constipation myalgia muscle pain diarrhea decreased appetite palmarplantar erythrodysesthesia syndrome skin reaction palms soles ripretinib also cause serious side effects including skin cancer hypertension high blood pressure cardiac dysfunction manifested ejection fraction decrease muscle left ventricle heart pumping well ripretinib may cause harm developing fetus newborn ripretinib approved medical use united states may approval ripretinib based results international multicenter randomized doubleblind placebocontrolled clinical trial enrolled participants advanced gastrointestinal stromal tumor gist received prior treatment imatinib sunitinib trial compared participants randomized receive ripretinib participants randomized receive placebo determine whether progression free survival pfs time initial treatment clinical trial growth cancer death longer ripretinib group compared placebo treatment trial participants received ripretinib mg placebo day cycles repeated tumor growth found disease progression participant experienced intolerable side disease progression participants randomized placebo given option switching trial conducted sites united states australia belgium canada france germany italy netherlands poland singapore spain united major efficacy outcome measure progressionfree survival pfs based assessment blinded independent central review bicr using modified recist lymph nodes bone lesions target lesions progressively growing new tumor nodule within preexisting tumor mass must meet specific criteria considered unequivocal evidence additional efficacy outcome measures included overall response rate orr bicr overall survival trial demonstrated statistically significant improvement pfs participants ripretinib arm compared placebo arm hr ci us food drug administration fda granted application ripretinib priority review fast track designations well breakthrough therapy designation orphan drug fda granted approval qinlock deciphera pharmaceuticals ripretinib approved medical use united states may australia july september committee medicinal products human use chmp adopted positive opinion recommending granting marketing authorization medicinal product qinlock intended treatment advanced gastrointestinal stromal tumour gist people received prior treatment three kinase applicant medicinal product deciphera pharmaceuticals netherlands ripretinib approved medical use european union november ripretinib international nonproprietary name inn united states adopted name httpsenwikipediaorgwikiripretinib